Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.

Multiple sclerosis (Houndmills, Basingstoke, England)·2020

Same author

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.

EBioMedicine·2020

Same author

[Ocrelizumab for treatment of multiple sclerosis].

Der Nervenarzt·2020

Same author

Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS.

Neurology(R) neuroimmunology & neuroinflammation·2020

Same author

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.

EBioMedicine·2020

Same author

COVID-19 and management of neuroimmunological disorders.

Nature reviews. Neurology·2020

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Principles of a new treatment algorithm in multiple sclerosis.

Hans-Peter Hartung¹, Xavier Montalban, Per Soelberg Sorensen

¹Department of Neurology, Heinrich-Heine-University Medical School, Düsseldorf, Germany. hans-peter.hartung@uni-duesseldorf.de

Expert Review of Neurotherapeutics

|March 8, 2011

Summary

New oral treatments for multiple sclerosis (MS) are emerging, offering alternatives to injections. This analysis helps determine their place in current MS treatment plans and anticipates future therapeutic strategies.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Related Experiment Videos

Last Updated: Jun 3, 2026

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

Published on: December 26, 2015

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

Neurology
Immunology
Pharmacology

Background:

Multiple sclerosis (MS) management is evolving with new therapeutic options.
The introduction of oral medications addresses patient preference for non-parenteral administration.
Fingolimod is the first FDA-approved oral MS treatment, with cladribine under review.

Purpose of the Study:

To analyze trial data for new oral MS therapies and existing treatments.
To integrate clinical experience and evolving definitions of treatment success in MS.
To propose an updated MS treatment algorithm and speculate on future directions.

Main Methods:

Review of clinical trial data for oral and parenteral MS therapies.
Application of practical clinical experience in MS management.
Consideration of current understanding of treatment success metrics in MS.

Main Results:

Oral therapies like fingolimod offer a new administration route for MS patients.
The efficacy and safety data of oral agents are being compared to established treatments.
Defining treatment success in MS is becoming more nuanced with new options.

Conclusions:

Oral agents represent a significant advancement in multiple sclerosis management.
The integration of these new therapies into treatment algorithms requires careful consideration.
Future MS treatment landscapes may include a wider array of oral and novel agents.